Corrigendum to ‘Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen’

Le résumé fourni par la source

The authors regret to note that Figures 2, 3, 4, and 5 contain a mistaken axis label in each of the graphs. For each graph, the x-axis label after zero is “6” months, but the correct value is “8” months. This mislabelling does not change interpretation of the results. The authors would like to apologise for any inconvenience caused. ____________________________ DOI of original article: Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersenNeuromuscular DisordersVol. 31Issue 4PreviewSpinal muscular atrophy (SMA) is a progressive neuromuscular disease affecting infants, children, and adults. It is a leading genetic cause of death in infants and children [1,2]. SMA is caused by deletions or mutations in the survival motor neuron 1 (SMN1) gene, which encodes for SMN protein [3]. Deficiency of SMN protein leads principally to degeneration of spinal cord alpha motor neurons and progressive muscular atrophy, particularly in the trunk and proximal limb muscles. The paralogous SMN2 gene differs from SMN1 and produces mostly truncated protein that is dysfunctional and rapidly degraded. Full-Text PDF Open Access

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.